<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050033</url>
  </required_header>
  <id_info>
    <org_study_id>DO608679A</org_study_id>
    <nct_id>NCT04050033</nct_id>
  </id_info>
  <brief_title>Evoke Radiofrequency Device for Improvement of Skin Appearance</brief_title>
  <official_title>Clinical Study to Evaluate the Performance of Evoke Radiofrequency Device for Improvement of Skin Appearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety, efficacy, patient comfort and patient
      satisfaction after Evoke treatment
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">August 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Change in Skin Appearance</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>Picture evaluation by blinded investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate rate of Change in Skin Appearance using 3D Photographic analysis</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>3D Photographic analysis will be conducted using QuantifiCare System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate changes in skin using VivoSight Optical Coherence Tomography (OCT) software</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>Non-invasive in vivo skin imaging will be taken with the VivoSight Optical Coherence Tomography (OCT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate changes in skin appearance comparing photographs using Mechanical Turk (MTurk). The pictures will be sent through the system and evaluated by crowd workers.</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>The pictures will be sent through the system and evaluated by crowd workers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Investigator assessment of the skin appearance improvement</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Investigator assessment of the skin appearance improvement comparing pre and post treatment using 0 - 4 -points Likert scale at 1 month, 3 months and 6 months follow up visits:
• 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Subject assessment of improvement and satisfaction</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Improvement assessment will be performed independently by the subject himself 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows:
• 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.
Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows:
• +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate histological changes to treatment area skin</measure>
    <time_frame>3 Months</time_frame>
    <description>Positive changes in histologic evaluation: up to 5 subjects will undergo biopsies of the treated area for histology at baseline and at 3M follow-up visit. Histological sections will be stained using elastin, H&amp;E and other collagen specific stains.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Improvement of Skin Appearance</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evoke Device</intervention_name>
    <description>Subjects will undergo treatment with Evoke Device</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Signed informed consent to participate in the study.

          -  Female and male subjects, 35 - 75 years of age at the time of enrolment

          -  If female, not pregnant, lactating and must be either post-menopausal, surgically
             sterilized, or using a medically acceptable form of birth control at least 3 months
             prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods
             with spermicide or abstinence).

          -  In addition, negative urine pregnancy test as tested before each treatment and at the
             last visit for women with childbearing potential (e.g. not menopause).

          -  General good health confirmed by medical history and skin examination of the treated
             area.

          -  Willing to have photographs and images taken of the treated areas to be used
             de-identified in evaluations, publications and presentations.

          -  The patients should be willing to comply with the study procedure and schedule,
             including the follow up visit, and will refrain from using any other aesthetic
             treatment methods for the last 6 months and during the entire study period.

        Exclusion Criteria:

          -  - Pacemaker or internal defibrillator, or any other active electrical implant anywhere
             in the body.

          -  Permanent implant in the treated area such as metal plates and screws, silicone
             implants or an injected chemical substance, unless deep enough in the periostal plane.

          -  Current or history of skin cancer, or current condition of any other type of cancer,
             or premalignant moles.

          -  Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled
             hypertension, and liver or kidney diseases.

          -  Pregnancy and nursing.

          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use
             of immunosuppressive medications.

          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex
             in the treatment area, may be treated only following a prophylactic regimen.

          -  Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.

          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, and
             rash.

          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and
             fragile skin.

          -  History of bleeding coagulopathies or use of anticoagulants in the last 10 days.

          -  Any surgery in treated area within 3 months prior to treatment.

          -  Six months delay is required if other recent treatments like light, CO2 laser or RF
             were performed on the same area.

          -  Use of Isotretinoin (Accutane®) within 6 months prior to treatment.

          -  As per the practitioner's discretion, refrain from treating any condition that might
             make it unsafe for the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erez Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Avance Plastic Surgery Institute 5570 Longley Lane, Suite A Reno, NV 89511</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Chia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BodySculpt 128 Central Park S New York, NY 10019</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avance Plastic Surgery Institute</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Square Laser Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BodySculpt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

